Tumorigenesis and Neoplastic Progression Contrasting Actions of Selective Inhibitors of Angiopoietin-1 and Angiopoietin-2 on the Normalization of Tumor Blood Vessels

Angiopoietin-1 (Ang1) and angiopoietin-2 (Ang2) have complex actions in angiogenesis and vascular remodeling due to their effects on Tie2 receptor signaling. Ang2 blocks Ang1-mediated activation of Tie2 in endothelial cells under certain conditions but is a Tie2 receptor agonist in others. We examined the effects of selective inhibitors of Ang1 (mL4-3) or Ang2 (L1-7[N]), alone or in combination, on the vasculature of human Colo205 tumors in mice. The Ang2 inhibitor decreased the overall abundance of tumor blood vessels by reducing tumor growth and keeping vascular density constant. After inhibition of Ang2, tumor vessels had many features of normal blood vessels (normalization), as evidenced by junctional accumulation of vascular endothelial-cadherin, junctional adhesion molecule-A, and platelet/endothelial cell adhesion molecule-1 in endothelial cells, increased pericyte coverage, reduced endothelial sprouting, and remodeling into smaller, more uniform vessels. The Ang1 inhibitor by itself had little noticeable effect on the tumor vasculature. However, when administered with the Ang2 inhibitor, the Ang1 inhibitor prevented tumor vessel normalization, but not the reduction in tumor vascularity produced by the Ang2 inhibitor. These findings are consistent with a model whereby inhibition of Ang2 leads to normalization of tumor blood vessels by permitting the unopposed action of Ang1, but decreases tumor vascularity primarily by blocking Ang2 actions.

[1]  D. Schadendorf,et al.  Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. , 2009, Cancer research.

[2]  Petros Koumoutsakos,et al.  Edge detection in microscopy images using curvelets , 2009, BMC Bioinformatics.

[3]  L. Ellis,et al.  VEGF-targeted therapy: mechanisms of anti-tumour activity , 2008, Nature Reviews Cancer.

[4]  Mark W Dewhirst,et al.  Inhibition of in vivo tumor angiogenesis and growth via systemic delivery of an angiopoietin 2-specific RNA aptamer. , 2008, The Journal of surgical research.

[5]  K. Ebnet Organization of multiprotein complexes at cell–cell junctions , 2008, Histochemistry and Cell Biology.

[6]  Lei Xu,et al.  Perivascular nitric oxide gradients normalize tumor vasculature , 2008, Nature Medicine.

[7]  Elisabetta Dejana,et al.  Functionally specialized junctions between endothelial cells of lymphatic vessels , 2007, The Journal of experimental medicine.

[8]  T. Mccauley,et al.  Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102. , 2007, Cancer research.

[9]  W. Shim,et al.  Angiopoietin: A TIE(d) Balance in Tumor Angiogenesis , 2007, Molecular Cancer Research.

[10]  D. McDonald,et al.  In Vivo Actions of Angiopoietins on Quiescent and Remodeling Blood and Lymphatic Vessels in Mouse Airways and Skin , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[11]  Laurent Demanet,et al.  Fast Discrete Curvelet Transforms , 2006, Multiscale Model. Simul..

[12]  D. Dumont,et al.  Activation of Tie2 by angiopoietin-1 and angiopoietin-2 results in their release and receptor internalization , 2006, Journal of Cell Science.

[13]  Takashi Urano,et al.  Angiopoietins and angiopoietin-like proteins in angiogenesis. , 2006, Endothelium : journal of endothelial cell research.

[14]  Ma Dong,et al.  Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .

[15]  Kristian Pietras,et al.  A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  D. McDonald,et al.  Cellular abnormalities of blood vessels as targets in cancer. , 2005, Current opinion in genetics & development.

[17]  R. Jain Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[18]  Y. M. Lee,et al.  Hypoxia-responsive element-mediated soluble Tie2 vector exhibits an anti-angiogenic activity in vitro under hypoxic condition. , 2005, International journal of oncology.

[19]  Lei Xu,et al.  Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. , 2004, Cancer cell.

[20]  Thomas Hartmann,et al.  Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. , 2004, Cancer cell.

[21]  Gavin Thurston,et al.  Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. , 2004, The American journal of pathology.

[22]  Elisabetta Dejana,et al.  Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. , 2004, Physiological reviews.

[23]  Elisabetta Dejana,et al.  Endothelial cell–cell junctions: happy together , 2004, Nature Reviews Molecular Cell Biology.

[24]  A. Carè,et al.  Angiopoietin decoy secreted at tumor site impairs tumor growth and metastases by inducing local inflammation and altering neoangiogenesis , 2004, Cancer Immunology, Immunotherapy.

[25]  衛藤 剛 Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma : possible in vivo regulation via induction of proteases , 2004 .

[26]  L. Ellis,et al.  Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors. , 2003, Cancer research.

[27]  P. Newman,et al.  Signal transduction pathways mediated by PECAM-1: new roles for an old molecule in platelet and vascular cell biology. , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[28]  H. Augustin,et al.  Angiopoietin-1 and Angiopoietin-2 Share the Same Binding Domains in the Tie-2 Receptor Involving the First Ig-like Loop and the Epidermal Growth Factor-like Repeats* , 2003, The Journal of Biological Chemistry.

[29]  M. Teh,et al.  Angiopoietin 1 promotes tumor angiogenesis and tumor vessel plasticity of human cervical cancer in mice. , 2002, Experimental cell research.

[30]  P. Campochiaro,et al.  Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. , 2002, Developmental cell.

[31]  Richard A. Lang,et al.  Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Rakesh K Jain,et al.  Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. , 2002, The American journal of pathology.

[33]  M. Teh,et al.  Inhibition of angiopoietin‐1 expression in tumor cells by an antisense RNA approach inhibited xenograft tumor growth in immunodeficient mice , 2001, International journal of cancer.

[34]  K. Alitalo,et al.  Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. , 2001, Cardiovascular research.

[35]  L. Ellis,et al.  The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer. , 2001, Cancer research.

[36]  I. Stamenkovic,et al.  Angiopoietin-2 is implicated in the regulation of tumor angiogenesis. , 2001, The American journal of pathology.

[37]  H. Augustin,et al.  Blood vessel maturation in a 3‐dimensional spheroidal coculture model: direct contact with smooth muscle cells regulates endothelial cell quiescence and abrogates VEGF responsiveness , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[38]  S. McLeskey,et al.  Expression and function of angiopoietin-1 in breast cancer , 2000, British Journal of Cancer.

[39]  Ji-Hye Kim,et al.  Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway , 2000, Oncogene.

[40]  G. Yancopoulos,et al.  New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF , 1999, Oncogene.

[41]  M. Corada,et al.  Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[42]  M. Dewhirst,et al.  Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie 2 ( cancer y adenovirus y soluble receptor y tumor angiogenesis ) , 1998 .

[43]  M. Dewhirst,et al.  Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. , 1997, The Journal of clinical investigation.

[44]  Thomas N. Sato,et al.  Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. , 1997, Science.

[45]  Pamela F. Jones,et al.  Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic Angiogenesis , 1996, Cell.

[46]  Pamela F. Jones,et al.  Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning , 1996, Cell.